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There is much evidence that degradation of the extracellular matrix is essential for the development of cholesteatomas and that this
is induced by activation of matrix metalloproteinases (MMPs). Vitamin D3 (VD3) has several well-recognised biological activities,
including suppression of MMP production. The present study, therefore, was undertaken to examine whether VD3 could suppress
MMP production from cholesteatoma keratinocytes in vitro. Keratinocytes (2.5 × 105 cells/mL) induced from cholesteatoma tissue
specimens were cultured with various concentrations of VD3. After one hour, lipopolysaccharide was added to the cell cultures at
100µg/mL. The culture supernatants were then collected and assayed for MMP-1 and MMP-3 by ELISA. We also used ELISA to
measure the levels of both TIMP (tissue inhibitor of metalloproteinase)-1 and TIMP-2 in culture supernatants. Addition of VD3
into keratinocyte cultures caused the suppression of MMP and TIMP production, which was increased by LPS stimulation. This was
dose-dependent. The present results showing the suppressive activity of VD3 on the production of MMPs, which are responsible
for tissue remodeling, strongly suggest that VD3 would be a good candidate for an agent in the medical treatment of, or prophylaxis
for, cholesteatomas.
INTRODUCTION
The cholesteatoma is well recognised as a skin growth
that occurs in an abnormal location, the middle ear be-
hind the eardrum. It is also accepted that, over time,
the cholesteatoma can increase in size and destroy the
surrounding delicate bones of the middle ear. Although
much eﬀort has been made to understand the mecha-
nisms of cholesteatoma formation, the precise mecha-
nisms are not well understood [1].
The extracellular matrix (ECM) and cell to ECM in-
teraction is essential for cell proliferation and migration
[1, 2]. It is well established that degradation of both
basement membrane and ECM is important for carci-
noma invasion, metastasis, and inﬂammatory proteolytic
events [3]. Furthermore, degradation of the tissues is also
accepted to be accomplished by the cooperative action
of several types of proteolytic enzymes, including ma-
trix metalloproteinases (MMPs) [1, 3]. In this regard,
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several researchers examined the presence of MMPs in
cholesteatoma tissues, and revealed the extensive expres-
sionofMMPs,suchasMMP-1,-2,-3,and-9[1,3,4].The
MMP inhibitor, ilomastat, has been eﬀective in reducing
protease activity and tissue destruction in alkali-injured
rabbit corneas [5] and the chinchilla middle ear infected
with Pseudomonas aeruginosa [6]. From these reports, it
is reasonable to speculate that the use of MMP inhibitors
may prevent cholesteatoma progression. However, to the
best of our knowledge, no reports have appeared in the
literature, examining the inﬂuence of MMP inhibitor(s)
on the prevention of the induction and the progression of
cholesteatomas.
1α,25-dihydroxyvitamin D3 (VD3) has several well-
recognised biological eﬀects on cell proliferation and dif-
ferentiation, including tissue remodeling, which is medi-
ated by MMPs [7, 8, 9]. These biological eﬀects of VD3
have been reported to be due, at least in part, to its sup-
pressive eﬀect on MMP production from chondrocytes
and osteoblastic cells. The present study wasthereforeun-
dertaken to examine whether VD3 could be used for the
medical treatment of and prophylaxis for cholesteatomas
by examining the inﬂuence of VD3 on MMP production
from keratinocytes in vitro.2005:4 (2005) Suppression of MMP Production by Vitamin D3 In Vitro 211
MATERIALS AND METHODS
Reagent
VD3 was donated from TEIJIN Co, Ltd (Tokyo,
Japan).Thiswasdissolved in dymethyl sulfoxide(DMSO)
at a concentration of 1 × 10−3 M and then diluted with
keratinocyte-SFM (SFM; SIGMA CHEMICALS Co Ltd,
St Louis, Mo, USA) at appropriate concentrations for ex-
periments. Lipopolysaccharide (LPS) extracted from Es-
cherichia coli was purchased from SIGMA CHEMICALS
Co, Ltd.
Inductionofkeratinocytes
Cholesteatomas were obtained surgically from ﬁve
patients under written informed consent, and the en-
tire study was approved by the Ethics Committee of
Showa University. Tissue samples were digested with
2.4U/mL Dispase II (Boehringer Mannhaim, Germany)
for 12hours at 4◦C. Epithelial sheets were then dissected,
cut into small pieces with scissors, and dissociated with
0.2% trypsin (GIBCO BRL, Gaithersburg, Md, USA) for
30minutesat37◦C.Thedissociatedcellswerewashedsev-
eral times with SFM supplemented with 500µg/mL strep-
tomycin, 500U penicillin, and 5.0µg/mL amphotericin
B. The cells were then seeded at a density of 1 ×106
cells/100-mm culture dishes, and the dishes were placed
at 37◦C in a humidiﬁed atmosphere containing 5% CO2.
The medium was changed every 3 days for 2–3 weeks un-
til conﬂuence was attained. Subsequently, the cells were
trypsinised, characterised with involucrinin staining, and
used as keratinocytes.
Cellculture
The cells were washed several times with SFM and in-
t r o d u c e di n t oe a c hw e l lo f2 4 - w e l lc u l t u r ep l a t e sa tac o n -
centration of 2.5 × 105 cells/mL in a volume of 1.0mL.
The cells were then stimulated with 100µg/mL LPS in
the presence or absence of various concentrations of VD3
in a ﬁnal volume of 2.0mL. VD3 treatment was started
60minutes before LPS stimulation. After 24hours, the
culture medium was removed and centrifuged, and the
supernatants were stored at −40◦C until use. For the ex-
amination of the inﬂuence of VD3 on mRNA expression
for MMPs and TIMPs, the cells were cultured in a simi-
lar manner for 12hours, and the cells were obtained and
stored at −80◦C until processed.
AssayforMMPsandTIMPsinculturesupernatants
MMP-2, MMP-9, TIMP-1, and TIMP-2 levels in cul-
ture supernatants were assayed using commercially avail-
able human MMP and TIMP ELISA test kits (Amersham
Biosciences, Bucks, UK) according to the manufacturer’s
recommendation.
AssayformRNAexpression
mRNA was extracted from keratinocytes using
µMACS mRNA isolation kits (Milteny Biotec GmbH,
Bergisch Gladbach, Germany) according to the manu-
facturer’s instructions. The ﬁrst-strand cDNA synthesis
from 1.0µg mRNA was performed using the Super Script
Preampliﬁcation System for cDNA synthesis (GIBCO
BRL). The polymerase chain reaction (PCR) mixture
consisted of 1.0µL of sample cDNA solution, 3.3µLo f
10× PCR buﬀer (Takara Shuzo Co, Ltd, Shiga, Japan),
2.6µL of dNTP mixture (Takara Shuzo), 1.0µLo fb o t h
sense and antisense primers, 0.2µLo fT a qD N Ap o l y -
merase (Takara Shuzo), and distilled water to give a ﬁnal
volume of 30µL. The primers used for RT-PCR were
5 -AGATCTTCTTCTTCAAGGACCGGTT-3  (sense)and
5 -GGCTGGTCAGTGGCTTGGGGTA-3  (anti-sense)
for MMP-2 [10], 5 -CCTCTGATGGCCCAGAATTGA-3 
(sense) and 5 -GAAATTGGCCACTCCCTGGGT-3 
(anti-sense) for MMP-3 [11], 5 -CACCCACAGACG-
GCCTTCTGCAAT-3  (sense) and 5 -AGTGTAGGTCTT-
GGTGAAGCC-3  (anti-sense) for TIMP-1 [11]5  -
CTCGCTGGACGTTGGAGGAAAGAA-3  (sense) and
5 -AGCCCATCTGGTACCTGTGGTTCA-3  (anti-sense)
f o rT I M P - 2[ 12], 5 -CGGAACCGCTCATTGCC-3  and
5 -ACCCACACTGTGCCCATCTA-3  for β-actin [10].
The PCR conditions were as follows: 4minutes at
94◦C, followed by 30 cycles of 30seconds at 94◦C,
30seconds at 58◦C, and 30seconds at 72◦C. After cycling,
there was a DNA extension period of 4 minutes at 72◦C.
EachPCRproduct(10µL)wasrunon3%agarosegels,vi-
sualised with a UV illuminator after SYBR Green staining
(BioWhittaker Molecular Applications, Rockland, Me)
and photographed. The intensity of the mRNA levels was
corrected by β-actin transcripts calculated with a densito-
meter.
Statisticalanalysis
The statistical signiﬁcance of the diﬀerence between
the control and experimental data was analysed using
ANOVA followed by Fisher’s PLSD test. A P value <. 05
was accepted as statistically signiﬁcant.
RESULTS
InﬂuenceofVD3ontheproductionofMMP
andTIMPfromkeratinocytesinvitro
The ﬁrst set of experiments was designed to exam-
ine the inﬂuence of VD3 on MMPs production from ker-
atinocytes in response to LPS stimulation. Keratinocytes
at a concentration of 2.5 × 105 cells/mL were stimu-
lated with 100.0µg/mL LPS for 24hours, and MMP-2
and MMP-3 levels in culture supernatants were exam-
ined by ELISA. As shown in Figure 1, addition of VD3
into cell cultures at less than 10−8 M did not cause the
suppression of MMP-2 production from keratinocytes:
the culture supernatants obtained from cells treated with
10−8 M contained similar levels of MMP-2 to those in
control cultures. However, VD3 at more than 10−7 M
signiﬁcantly suppressed the ability of cells to produce
MMP-2 induced by LPS stimulation (Figure 1). We next212 Hitome Kobayashi et al 2005:4 (2005)
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Figure 1. Suppressive activity of vitamin D3 on MMP-2 and MMP-3 production from keratinocytes in vitro. Keratinocytes (2.5 ×
105 cells/mL) derived from cholesteatoma tissues were stimulated with 100µg/mL lipopolysaccharide (LPS) in the presence of various
concentrations of vitamin D3 for 24hours. MMP-2 levels in culture supernatants were examined by ELISA. Each set of data was
expressed as the mean ng/mL ± SEM of ﬁve diﬀerent subjects.
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Figure 2. Suppressive activity of vitamin D3 on TIMP-1 and TIMP-2 production from keratinocytes in vitro. Details are shown in
the legend of Figure 1.
examined the inﬂuence of VD3 on MMP-3 production
from keratinocytes. VD3 exerted dose-dependent sup-
pressive eﬀects on MMP-3 production (Figure 1). The
minimum concentration of VD3 which showed signif-
icant suppression was 10−8 M. The third set of experi-
ments was performed to examine the inﬂuence of VD3
on TIMP-1 and TIMP-2 production from keratinocytes.
The data in Figure 2 clearly showed the dose-dependent
suppressive activity of VD3 on TIMP-1 and TIMP-2 pro-
duction. The minimum concentrations of VD3 which
showed signiﬁcant suppression were 10−8 Mf o rT I M P - 1
and 10−9 M for TIMP-2.
InﬂuenceofVD3onmRNAexpression
The ﬁnal set of experiments was carried out to exam-
ine the possible mechanisms by which VD3 could sup-
press the production of MMPs and TIMPs from ker-
atinocytes in response to LPS stimulation. Cells were cul-
turedwith100µg/mLLPSinthepresenceof0,10−9,10 −8,2005:4 (2005) Suppression of MMP Production by Vitamin D3 In Vitro 213
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Figure 3.InﬂuenceofvitaminD3onmRNAexpressionforMMP-2andMMP-3inkeratinocytesafterLPSstimulation.Keratinocytes
(2.5 × 105 cells/mL) derived from cholesteatoma tissues were stimulated with 100µg/mL lipopolysaccharide (LPS) in the presence of
various concentrations of vitamin D3 for 12hours. mRNA expressions for MMP-2 and MMP-3 were examined by RT-PCR. Each set
of data was expressed as the mean ratio (target/β-actin) ±SEM of ﬁve diﬀerent subjects.
and10−7 MVD3for12hours.LevelsofmRNAexpression
were evaluated by RT-PCR. As shown in Figure 3, the ad-
dition of VD3 at 10−9 M could not suppress the expres-
sion of mRNA for MMP-2 and MMP-3: these mRNA lev-
elsincellstreatedwithVD3werenearlyidentical(notsig-
niﬁcant) to those observed in VD3-nontreated cells (LPS
alone). However, MMP-2 mRNA expression was signiﬁ-
cantly suppressed by the addition of 10−7 M VD3 (Figure
3). Similarly, MMP-3 mRNA expression was also sup-
pressed by treatment of cell with 10−8 M VD3 (Figure
3). We ﬁnally examined the inﬂuence of VD3 on TIMP
mRNAexpression.ThedatainFigure4clearlyshowedthe
suppressive activity of VD3 on TIMP mRNA expression
in which the minimum concentrations of VD3 showing
suppression of mRNA expression were 10−8 Mf o rT I M P -
1a n d1 0 −9 M for TIMP-2.
DISCUSSION
Cholesteatomas are characterised by abnormal cell
proliferation resulting in the accumulation of keratin de-
bris, destruction of the surrounding structures, and inva-
sionoftheinnerearorintracranialcavity.Althoughinitial
treatmentofthecholesteatomaisacceptedasconsistingof
careful cleaning of the ear and topical application of an-
tibiotics or steroids, large or complicated cholesteatomas
require surgical treatment to protect the patients from
serious complications. In addition, cholesteatomas are
well known to recur, even after surgical removal. Fur-
thermore, a surgical procedure may not be possible in
all cholesteatoma patients, such as elderly patients with
a poor general medical condition. Therefore, the devel-
opment of a minimally invasive agent or agents which
couldbeusedforthetreatmentofandprophylaxisagainst
cholesteatomas has been strongly anticipated.
The present results clearly showed the suppressive ef-
fect of VD3 on the ability of keratinocytes to produce
MMP-2 and MMP-3 in response to LPS stimulation.
The study also demonstrated that VD3 exerted a suppres-
sive eﬀe c to nT I M P - 1a n dT I M P - 2p r o d u c t i o nf r o mk e r -
atinocytes induced by LPS stimulation. Moreover, these
inhibitory actions of VD3 may be mediated, in part, by its
suppressive eﬀect on the expression of MMPs and TIMPs
mRNA.
Histological observations of cholesteatoma tissues
have revealed a benign keratinizing squamous cell cyst
made up of three components, the cystic content, the ma-
trix, and the perimatrix. The cystic content is composed
of fully-diﬀerentiated nucleate keratine squames. The
matrix contains the keratinizing squamous epithelium214 Hitome Kobayashi et al 2005:4 (2005)
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Figure 4. Inﬂuence of vitamin D3 on mRNA expression for TIMP-1 and TIMP-2 in keratinocytes after LPS stimulation. Details are
shown in the legend of Figure 3.
lining a cyst-like structure. The perimatrix or lamina pro-
pria is the peripheral part of the cholesteatoma consisting
of granulation tissue, which contains cholesterol crystals.
The perimatrix layer is also in contact with bone and may
result in bone destruction. These histological changes are
now called tissue remodeling, and involve extensive alter-
ations of the tissue ECM.
The ECM is involved in tissue homeostasis and in
pathologic conditions such as tumour invasion and in-
ﬂammation. Two groups of proteins, MMPs and their
counter-regulatory inhibitors, TIMPs, are accepted to
be the important factors for maintenance of ECM ho-
moeostasis. TheMMPsareagroupofzinc-containing en-
zymes that are capable of digesting the ECM and base-
ment membrane [13]. Among them, MMPs-2 and -3 de-
grade native type IV and VII collagen and denatured col-
lagen, as well as laminin and proteoglycan, which are the
most important components of ECM, basement mem-
brane, and bone [14]. These MMPs are produced by
numerous cell types, including keratinocytes and ﬁbrob-
lasts in response to inﬂammatory stimulation [15, 16].
MMPs also appear to be responsible for microvascu-
lar permeability leading to oedema and enhancement of
cell transmigration, especially in the case of osteoclasts
[15, 16]. From these reports, the present results show-
ing the inhibitory action of VD3 on both MMP-2 and
-3 production from keratinocytes may be interpreted to
mean that topical application of VD3 to the external au-
ditory canal and tympanic membrane could prevent the
induction of cholesteatomas. This suggestion may be sup-
ported by the ﬁnding that topical application of VD3 can
favourably modify psoriasis vulgaris skin lesions, which
arecharacterisedbytheabnormalgrowthofkeratinocytes
withtheintenseinﬁltrationofinﬂammatorycells[17,18].
Most MMPs are secreted from the cells as inactive proen-
zyme and cleaved extracellularly to produce the active
forms [19]. The extracellular activity of MMPs is regu-
lated by TIMPs, which are secreted by the same cell types
that produce MMPs [19]. Besides MMP inhibitory ac-
tivity, TIMPs have many biological functions associated
with cell growth-stimulating activity [20]. The present re-
sults clearly showed that VD3 could suppress the ability
ofkeratinocytestoproduceTIMP-1andTIMP-2,suggest-
ing that VD3 could suppress abnormal cell growth in the
surrounding tissues of cholesteatomas, and result in the
inhibition of ECM remodeling and the development of
cholesteatomas.
In conclusion, the present results might suggest that
VD3 would be a good candidate for an agent in the medi-
cal treatment of or prophylaxis against cholesteatomas.
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